Диссертация (1150007), страница 16
Текст из файла (страница 16)
Estradiol stimulates apolipoprotein AI–butnot A-II–containing particle synthesis and secretion by stimulating mRNAtranscription rate in Hep G2 cells // Arterioscler. Thromb. Vasc. Biol. – 1998. – Vol.18. – № 6. – P. 999–1006.41.Villar I.C., Hobbs A.J., Ahluwalia A. Sex differences in vascular function:implication of endothelium-derived hyperpolarizing factor // J. Endocrinol.
– 2008. –Vol. 197. – № 3. – P. 447–462.42.Rosselli M., Imthurn B., Keller P.J., Jackson E.K., Dubey R.K. Circulating NitricOxide (Nitrite/Nitrate) Levels in Postmenopausal Women Substituted With 17βEstradiol and Norethisterone Acetate A Two-Year Follow-up Study // Hypertension –1995. – Vol. 25. – № 4. – P.
848–853.43.Mendelsohn M.E. Genomic and nongenomic effects of estrogen in the vasculature //Am. J. Cardiol. – 2002. – Vol. 90. – № 1. – P. F3–F4.44.Rosenfeld C.R., Cox B.E., Roy T., Magness R.R. Nitric oxide contributes to estrogeninduced vasodilation of the ovine uterine circulation. // J. Clin. Invest. – 1996. – Vol.98. – № 9. – P. 2158.45.Lantin-Hermoso R.L., Rosenfeld C.R., Yuhanna I.S., German Z., Chen Z., Shaul P.W.Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary arteryendothelium // Am. J.
Physiol. Cell. Mol. Physiol. – 1997. – Vol. 17. – № 1. – P. 119–126.46.Voss M.R., Stallone J.N., Li M., Cornelussen R.N.M., Knuefermann P., KnowltonA.A. Gender differences in the expression of heat shock proteins: the effect ofestrogen // Am. J. Physiol. Circ. Physiol. – 2003. – Vol. 285. – № 2. – P. H687–H692.47.Van der Weerd L., Lythgoe M.F., Badin R.A., Valentim L.M., Akbar M.T., deBelleroche J.S., Latchman D.S., Gadian D.G. Neuroprotective effects of HSP70113overexpression after cerebral ischaemia—an MRI study // Exp. Neurol.
– 2005. – Vol.195. – № 1. – P. 257–266.48.Gogvadze V., Orrenius S. Mitochondrial regulation of apoptotic cell death // Chem.Biol. Interact. – 2006. – Vol. 163. – № 1. – P. 4–14.49.Kroemer G., Martin S.J. Caspase-independent cell death // Nat. Med. – 2005. – Vol.11. – № 7. – P. 725–730.50.Matsumori Y., Hong S.M., Aoyama K., Fan Y., Kayama T., Sheldon R.A., VexlerZ.S., Ferriero D.M., Weinstein P.R., Liu J. Hsp70 overexpression sequesters AIF andreduces neonatal hypoxic/ischemic brain injury // J. Cereb.
Blood Flow Metab. –2005. – Vol. 25. – № 7. – P. 899–910.51.Kuan C.-Y., Burke R.E. Targeting the JNK signaling pathway for stroke andParkinson’s diseases therapy // Curr. Drug Targets-CNS Neurol. Disord. – 2005. –Vol. 4. – № 1. – P. 63–67.52.Barati M.T., Rane M.J., Klein J.B., McLeish K.R. A proteomic screen identifiedstress-induced chaperone proteins as targets of Akt phosphorylation in mesangial cells// J. Proteome Res. – 2006. – Vol. 5. – № 7. – P. 1636–1646.53.Yue W., Santen R.., Wang J.-P., Li Y., Verderame M.., Bocchinfuso W.., Korach K..,Devanesan P., Todorovic R., Rogan E.., et al.
Genotoxic metabolites of estradiol inbreast: potential mechanism of estradiol induced carcinogenesis // J. Steroid Biochem.Mol. Biol. – 2003. – Vol. 86. – № 3-5. – P. 477–486.54.Santen R.J. To block estrogen’s synthesis or action: that is the question // J. Clin.Endocrinol. Metab. – 2002. – Vol. 87. – № 7. – P. 3007–3012.55.Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., Henderson B.E.
Increased celldivision as a cause of human cancer // Cancer Res. – 1990. – Vol. 50. – № 23. – P.7415–7421.56.Liehr J.G. Is Estradiol a Genotoxic Mutagenic Carcinogen? 1 // Endocr. Rev. – 2000.– Vol. 21. – № 1. – P. 40–54.57.Cavalieri E., Frenkel K., Liehr J.G., Rogan E., Roy D. Estrogens as endogenousgenotoxic agents—DNA adducts and mutations // JNCI Monogr.
– 2000. – Vol. 2000.– № 27. – P. 75–94.58.Lu F., Zahid M., Wang C., Saeed M., Cavalieri E.L., Rogan E.G. Resveratrol preventsestrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells //Cancer Prev. Res. – 2008. – Vol. 1. – № 2. – P. 135–145.59.Maclusky N.J., Naftolin F., Krey L.C., Franks S. The catechol estrogens // J. SteroidBiochem.
– 1981. – Vol. 15. – P. 111–124.11460.Fishman J. Aromatic hydroxylation of estrogens // Annu. Rev. Physiol. – 1983. – Vol.45. – № 1. – P. 61–72.61.Nebert D.W. Elevated estrogen 16α-hydroxylase activity: is this a genotoxic ornongenotoxic biomarker in human breast cancer risk? // J. Natl. Cancer Inst. – 1993. –Vol. 85. – № 23.
– P. 1888–1891.62.Muti P., Westerlind K., Wu T., Grimaldi T., Schünemann H., Freudenheim J.L., HillH., Carruba G., Bradlow L. Urinary estrogen metabolites and prostate cancer: a case–control study in the United States // Cancer Causes Control – 2002. – Vol. 13. – № 10.– P. 947–955.63.Adlercreutz H., Fotsis T., Bannwart C., Hämäläinen E., Bloigu S., Ollus A. Urinaryestrogen profile determination in young Finnish vegetarian and omnivorous women //J. Steroid Biochem. – 1986. – Vol. 24. – № 1. – P.
289–296.64.Hoffman A.R., Paul S.M., Axelrod J. Catecholestrogen synthesis and metabolism byhuman breast tumors in vitro // Cancer Res. – 1979. – Vol. 39. – № 11. – P. 4584–4587.65.Liehr J.G., Wan-Fen F., Sirbasku D.A., Ari-Ulubelen A. Carcinogenicity of catecholestrogens in Syrian hamsters // J.
Steroid Biochem. – 1986. – Vol. 24. – № 1. – P.353–356.66.Li S.A., Purdy R.H., Li J.J. Variations in catechol O-methyltransferase activity inrodent tissues: possible role in estrogen carcinogenicity // Carcinogenesis – 1989. –Vol. 10. – № 1. – P. 63–67.67.Bradlow H.L., Telang N.T., Sepkovic D.W., Osborne M.P. 2-hydroxyestrone:the’good'estrogen // J.
Endocrinol. – 1996. – Vol. 150. – № 3 Suppl. – P. S259–S265.68.Butterworth M., Lau S.S., Monks T.J. Formation of catechol estrogen glutathioneconjugates and gamma-glutamyl transpeptidase-dependent nephrotoxicity of 17betaestradiol in the golden Syrian hamster. // Carcinogenesis – 1997. – Vol. 18. – № 3. –P. 561–567.69.Monks T.J., Lau S.S. Biological reactivity of polyphenolic-glutathione conjugates //Chem. Res.
Toxicol. – 1997. – Vol. 10. – № 12. – P. 1296–1313.70.Beall H.D., Liu Y., Siegel D., Bolton E.M., Gibson N.W., Ross D. Role of NAD (P)H: quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNAdamage by streptonigrin // Biochem. Pharmacol.
– 1996. – Vol. 51. – № 5. – P. 645–652.71.Floyd R.A. The role of 8-hydroxyguanine in carcinogenesis // Carcinogenesis – 1990.– Vol. 11. – № 9. – P. 1447–1450.72.Monks T.J., Hanzlik R.P., Cohen G.M., Ross D., Graham D.G. Quinone chemistryand toxicity // Toxicol. Appl. Pharmacol. – 1992. – Vol. 112. – № 1. – P. 2–16.11573.Bolton J.L., Pisha E., Zhang F., Qiu S.
Role of quinoids in estrogen carcinogenesis //Chem. Res. Toxicol. – 1998. – Vol. 11. – № 10. – P. 1113–1127.74.Klaassen C.D. Casarett and Doull’s Toxicology: the basic science of poisons // NewYork Macmillan Publ. – 2013.75.Singer B., Hang B. What structural features determine repair enzyme specificity andmechanism in chemically modified DNA? // Chem.
Res. Toxicol. – 1997. – Vol. 10. –№ 7. – P. 713–732.76.Loeb L.A., Preston B.D. Mutagenesis by apurinic/apyrimidinic sites // Annu. Rev.Genet. – 1986. – Vol. 20. – № 1. – P. 201–230.77.Fournier D., Poirier D. Estradiol dimers as a new class of steroid sulfatase reversibleinhibitors // Bioorg. Med. Chem. Lett. – 2009. – Vol. 19. – № 3. – P. 693–696.78.Jensen E. V, Jordan V.C. The estrogen receptor a model for molecular medicine //Clin. Cancer Res. – 2003. – Vol. 9. – № 6.
– P. 1980–1989.79.Poirier D. New cancer drugs targeting the biosynthesis of estrogens and androgens //Drug Dev. Res. – 2008. – Vol. 69. – № 6. – P. 304–318.80.Poirier D., Maltais R. Solid-phase organic synthesis (SPOS) of modulators ofestrogenic and androgenic action // Mini Rev. Med. Chem. – 2006. – Vol. 6. – № 1.
–P. 37–52.81.Pasqualini J.R. The selective estrogen enzyme modulators in breast cancer: a review //Biochim. Biophys. Acta (BBA)-Reviews Cancer – 2004. – Vol. 1654. – № 2. – P.123–143.82.Eisen A., Trudeau M., Shelley W., Messersmith H., Pritchard K.I. Aromataseinhibitors in adjuvant therapy for hormone receptor positive breast cancer: asystematic review // Cancer Treat. Rev. – 2008. – Vol. 34. – № 2.
– P. 157–174.83.Subramanian A., Salhab M., Mokbel K. Oestrogen producing enzymes and mammarycarcinogenesis: a review // Breast Cancer Res. Treat. – 2008. – Vol. 111. – № 2. – P.191–202.84.Suzuki T., Miki Y., Nakata T., Shiotsu Y., Akinaga S., Inoue K., Ishida T., KimuraM., Moriya T., Sasano H. Steroid sulfatase and estrogen sulfotransferase in normalhuman tissue and breast carcinoma // J. Steroid Biochem. Mol. Biol. – 2003. – Vol.86.
– № 3. – P. 449–454.85.Howarth N.M., Purohit A., Robinson J.J., Vicker N., Reed M.J., Potter B.V.L.Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: homology modelconstruction and docking studies // Biochemistry – 2002. – Vol. 41. – № 50. – P.14801–14814.11686.Purohit A., Williams G.J., Howarth N.M., Potter B.V.L., Reed M.J. Inactivation ofsteroid sulfatase by an active site-directed inhibitor, estrone-3-O-sulfamate //Biochemistry – 1995.
– Vol. 34. – № 36. – P. 11508–11514.87.Li P.K., Pillai R., Dibbelt L. Estrone sulfate analogs as estrone sulfatase inhibitors //Steroids – 1995. – Vol. 60. – № 3. – P. 299–306.88.Woo L.W., Lightowler M., Purohit A., Reed M.J., Potter B.V.L. Heteroatomsubstituted analogues of the active-site directed inhibitor estra-1, 3, 5 (10)-trien-17one-3-sulphamate inhibit estrone sulphatase by a different mechanism // J. SteroidBiochem. Mol. Biol.
– 1996. – Vol. 57. – № 1. – P. 79–88.89.Schreiner E.P., Billich A. Estrone formate: a novel type of irreversible inhibitor ofhuman steroid sulfatase // Bioorg. Med. Chem. Lett. – 2004. – Vol. 14. – № 19. – P.4999–5002.90.Bubert C., Leese M.P., Mahon M.F., Ferrandis E., Regis-Lydi S., Kasprzyk P.G.,Newman S.P., Ho Y.T., Purohit A., Reed M.J. 3, 17-Disubstituted 2-alkylestra-1, 3, 5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity // J.
Med.Chem. – 2007. – Vol. 50. – № 18. – P. 4431–4443.91.Liehr J.G. 2-Fluoroestradiol. Separation of estrogenicity from carcinogenicity. // Mol.Pharmacol. – 1983. – Vol. 23. – № 2. – P. 278–281.92.Stalford A.C., Maggs J.L., Gilchrist T.L., Park B.K.
Catecholestrogens as mediatorsof carcinogenesis: correlation of aromatic hydroxylation of estradiol and itsfluorinated analogs with tumor induction in Syrian hamsters. // Mol. Pharmacol. –1994. – Vol. 45. – № 6. – P. 1259–1267.93.Ashburn S.P., Han X., Liehr J.G. Microsomal hydroxylation of 2-and 4fluoroestradiol to catechol metabolites and their conversion to methyl ethers: catecholestrogens as possible mediators of hormonal carcinogenesis. // Mol.
Pharmacol. –1993. – Vol. 43. – № 4. – P. 534–541.94.Valette A., Meignen J.M., Mercier L., Liehr J.G., Boyer J. Effects of 2-fluoroestradiolon lipid metabolism in the ovariectomized rat // J. Steroid Biochem. – 1986. – Vol.25. – № 4. – P. 575–578.95.Belov V.N., Dudkin V.Y., Urusova E. a., Starova G.L., Selivanov S.I., Nikolaev S.V., Eshchenko N.D., Morozkina S.N., Shavva a.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
